Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $112.5052W HIGH $192.85
Volume
220.61 K
Value Traded
87.39 M
Short % Float
6.17%
-1.38%Week
-2.37%1 Month
+1.79%3 Month
+25.06%6 Month
-34.04%5 Year
+2,399.54%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.93 B
EPS (TTM)
1.84
P/E Ratio
85.44
Ent. Value
4.86 B
Total Shares
25.00 M
Float Shares
24.56 M
Insiders
1.77%
Institutions
104.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ICUI Catalyst Timeline
Dated clinical, regulatory and corporate events for ICU Medical, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ICU Medical, Inc.
5Total events
0Upcoming
1Tier-1 (high impact)
2025 to 2026Coverage
Event history 4
▼RecallCMC / Inspection
Otsuka ICU Medical issues voluntary nationwide recall of one lot of 0.9% Sodium Chloride Injection, USP 100 mL due to potential mix-up with 10 mEq Potassium Chloride Injection
●Manufacturing MilestoneCMC / Inspection
End of US distribution period for affected lot of 0.9% Sodium Chloride Injection, USP
●Manufacturing MilestoneCMC / Inspection
Affected lot of 0.9% Sodium Chloride Injection, USP distributed in the United States
●Manufacturing MilestoneCMC / Inspection
Affected lot 1042188 of 0.9% Sodium Chloride Injection, USP manufactured
Past FDA Catalysts and PDUFA Decisions
How ICUI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2020-04-29 | Mannitol 15% In Plastic Container (mannitol) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 91%
Small Cap(rank 599 of 658)
Percentile Rank
ICU Medical, Inc. faces pipeline headwinds (22/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ICUI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sanzone Virginia RuthOfficer (VP, General Counsel) | Sell | -2,202 17,258 held | $167.67 | 09/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ICUI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 1.3 % (116.7 %) | 7.48 M | 51.00 K | 85.79% ( 23.55 K) |
ICUI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ICUI ranks across every disease it competes in
Competitive Position is a premium feature
See how ICUI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialICUI News
ICUIOtsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection
Otsuka ICU Medical LLC has issued a voluntary recall for a lot of 0.9% Sodium Chloride Injection due to a labeling mix-up that may result in the product containing Potassium Chloride instead. This poses significant health risks, particularly for vulnerable populations. The recall affects products distributed in the U.S. between December 2025 and June 2026, and customers are advised to quarantine the affected products and return them.
Read more →ICUIICU Medical to Participate in Upcoming Investor Conferences
ICU Medical, Inc. announced its participation in two upcoming investor conferences. The company will engage in one-on-one meetings and fireside chats at the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Live audio webcasts of these discussions will be available on their website.
Read more →ICUI▲ +10.9%on this news
ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
ICU Medical reported a 1% increase in GAAP revenue for Q2 2026, with adjusted diluted earnings per share rising to $2.37. The company updated its fiscal year 2026 guidance, projecting higher net income and earnings per share. However, the divestiture of the IV Solutions business has affected year-over-year comparisons.
Read more →ICUIICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call
ICU Medical, Inc. has announced the schedule for its second quarter 2026 earnings release and conference call. The earnings will be released on August 6, 2026, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call will be accessible via phone and webcast, ensuring investor engagement.
Read more →ICUIOtsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America
Otsuka ICU Medical LLC has announced a significant expansion of its IV solutions manufacturing, investing over $500 million in a new facility in Austin, Texas. This expansion aims to improve supply chain resiliency and accelerate the development of non-DEHP products. It marks a key milestone in the joint venture's commitment to enhance IV solutions manufacturing in North America.
Read more →ICUIICU Medical Announces First Quarter 2026 Results
ICU Medical reported its first quarter 2026 financial results, showing a 12% decline in GAAP revenue to $530.2 million compared to the previous year. However, non-GAAP organic revenue increased by 1% when excluding the impact of the IV Solutions divestiture. The company achieved a GAAP net income of $30.1 million, a significant turnaround from a loss in the prior year. The gross margin improved to 39%, indicating better operational efficiency.
Read more →ICUIICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
ICU Medical, Inc. has announced the timing for its first quarter 2026 earnings release and conference call. The earnings report will be available on May 7, 2026, followed by a conference call at 4:30 p.m. ET. This call will allow stakeholders to discuss the results and gain insights into the company's performance.
Read more →ICUIICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance
ICU Medical, Inc. reported its financial results for the fourth quarter of 2025, revealing a revenue decline to $540.7 million compared to $629.8 million in the previous year. Despite a minor improvement in gross margin to 38%, the company experienced a GAAP net loss of $(15.7) million. Looking forward, the company has provided guidance for fiscal year 2026, estimating net income between $26 million and $44 million, alongside adjusted EBITDA projections of $400 million to $430 million. Vital Care revenue suffered a significant drop, highlighting challenges within specific product lines.
Read more →ICUIICU Medical Announces Time of Fourth Quarter 2025 Earnings Conference Call
ICU Medical, Inc. has announced the schedule for its fourth quarter 2025 earnings release and conference call. The results will be disclosed on February 19, 2026, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call will be accessible via phone and webcast, ensuring broad participation.
Read more →ICUIICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
ICU Medical, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The presentation is scheduled for January 14 at 1:30 p.m. PT. Additionally, the company will hold one-on-one meetings with investors on the same day. The event will be webcast live and available for replay.
Read more →ICUIICU Medical to Participate at the Piper Sandler 37th Annual Healthcare Conference
ICU Medical, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. The company's management will host a fireside chat on December 4 at 10:00 a.m. PT and will also hold one-on-one meetings with investors. The event will be webcast live, with a replay available afterward.
Read more →ICUI▲ +8.1%on this news
ICU Medical Announces Third Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
ICU Medical reported its third quarter 2025 financial results, showing a revenue of $537 million, down from $589.1 million year-over-year. Despite a GAAP net loss of $3.4 million, the company improved its adjusted diluted earnings per share to $2.03. ICU Medical has updated its fiscal year 2025 guidance, projecting a reduced net loss and increased adjusted EBITDA.
Read more →ICUIICU Medical Announces Time of Third Quarter 2025 Earnings Conference Call
ICU Medical, Inc. has announced the timing for its third quarter 2025 earnings release and conference call. The earnings results will be released on November 6, 2025, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call will be accessible via phone and webcast, ensuring investor participation.
Read more →ICUIICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
ICU Medical Inc. announced its second quarter 2025 financial results, revealing revenues of $548.9 million, a decline compared to last year's $596.5 million. However, the company experienced a favorable net income of $35.3 million this quarter, a notable contrast to a loss in the same period last year. Additionally, the gross margin improved to 38%. The company has also updated its fiscal year 2025 guidance, adjusting its estimates for GAAP net loss and diluted earnings per share.
Read more →ICUIICU Medical Announces First Quarter 2025 Results
ICU Medical, Inc. reported its financial results for Q1 2025, showing a revenue increase to $604.7 million compared to $566.7 million in Q1 2024. The gross profit also rose, leading to an improved gross margin of 35%. Despite these gains, the company faced a net loss of $(15.5) million. The CEO noted that results were generally in line with expectations.
Read more →ICUIICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. have successfully formed a joint venture named Otsuka ICU Medical LLC. This partnership aims to enhance the IV solutions manufacturing capabilities in North America, combining OPF's global manufacturing expertise with ICU Medical's local production. The collaboration is expected to improve supply chain resiliency and introduce innovative technologies.
Read more →ICUIICU Medical Introduces Its New Category of Infusion Devices With FDA Clearances of Plum Solo™ and Plum Duo™ Precision IV Pumps
ICU Medical has received FDA clearance for its new Plum Solo and Plum Duo precision IV pumps, enhancing its IV Performance Platform. These devices aim to reduce infusion delivery variability and provide accurate data for patient care. The Plum Solo is a single-channel pump complementing the dual-channel Plum Duo, both ensuring ±3% accuracy in various conditions. This launch marks a significant advancement in infusion therapy technology.
Read more →ICUIICU Medical to Present at the 24th Annual Needham Virtual Healthcare Conference
ICU Medical will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. The presentation is scheduled for 8:00 a.m. PT and will be available via live webcast. Additionally, company management will hold one-on-one meetings on the same day, providing opportunities for direct engagement with investors.
Read more →About ICU Medical, Inc.
Headquarters951 CALLE AMANECER, SAN CLEMENTE, CA, 92763-6212
BIOPHARMAWATCH ELITE PLUS
Trade the next ICUI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime